Latest from ISC 2017
Efficacy of triple antiplatelet therapy compared with current guideline-based therapy for the prevention of recurrent stroke was evaluated in the TARDIS trial.
More patients receiving VNS experienced enhanced arm movement over a 90-day period.
Restarting anticoagulation after both nonlobar and lobar ICH was associated with decreased mortality.
Men were more likely than women to be treated with IV tPA within 30 minutes of arrival at a hospital.
As more patients survive ICH, emphasis is slowly shifting from survival to improving ICH-related morbidity and optimization of functional recovery.
The results provide good evidence for the use of contact aspiration in ischemic stroke.
Optimal antiplatelet treatment has yet to be determined for stroke survivors with prior intracerebral hemorrhage.
The co-presentation of headache at stroke onset in children may provide clues to underlying pathophysiologic mechanisms.
Psychological distress may cause changes within cells that trigger inflammation and oxidative stress, both of which are believed to increase stroke risk.
Delays related to the determination of treatment eligibility increased door-to-needle times by more than 30 minutes compared with patients with no delays.
Sign Up for Free e-newsletters
Check out what's trending
Neurology Advisor Articles
- OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms
- History of Migraine Associated With Higher Risk for Cochlear Disorders
- Patent Foramen Ovale Closure for Stroke Prevention: Key Principles for Clinical Practice
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- A Model for Predicting Quality of Life Improvements After Deep Brain Stimulation
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- First-in-Class Therapy Approved for Polyneuropathy Caused by hATTR
- High Anxiety Symptoms Prevalent in Epilepsy, Mesial Temporal Sclerosis
- Advance Care Planning Doesn't Aid Quality of Life
- Variation in Specialty Drug Coverage Across Health Plans
- Alcohol Exposure Via Breastmilk May Affect Infant Development